Skip to content
Screener

Xencor XNCR Pre-Tax Income

Pre-Tax Income at other companies

Amgen logo
AmgenAMGN
$2.77B+76.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.53B+0.6%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$58.97M-62.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$52.84M-34.5%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$10.09M-123%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$111.32M-30.5%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.6B+221%
Enterprise value$1.73B+159%
P/S15.3×+11.9×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Asset impairment charges(797)(1,858)(797)(6,723)
Other, net434(17)830(48)
Total other income (expense)15,1492,097(35,625)(2,985)
Loss before income tax expense (benefit) and noncontrolling interest(21,919)(31,075)(150,555)(79,340)
Income tax (benefit) expense(190)(250)90117
Net loss including noncontrolling interest(21,729)(30,825)(150,645)(79,457)
Net loss attributable to noncontrolling interest(214)
Net loss attributable to Xencor, Inc.$(21,729)$(30,825)$(150,645)$(79,243)

Item 1. Financial Statements

FAQ

What is Xencor's pre-tax income?
Xencor (XNCR) reported pre-tax income of -$21.92M in Q2 2026.
How has Xencor's pre-tax income changed year-over-year?
Xencor's pre-tax income increased by 29.5% year-over-year, from -$31.08M to -$21.92M.
What is the long-term trend for Xencor's pre-tax income?
Over 2 years (2023 to 2025), Xencor's pre-tax income has grown at a -13.4% compound annual growth rate (CAGR), from -$119.63M to -$89.63M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Xencor's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude